Orchestra BioMed (NASDAQ:OBIO) Director Jason Aryeh Purchases 8,971 Shares of Stock

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Director Jason Aryeh acquired 8,971 shares of the company’s stock in a transaction on Friday, May 15th. The stock was bought at an average price of $3.90 per share, for a total transaction of $34,986.90. Following the purchase, the director owned 117,453 shares in the company, valued at approximately $458,066.70. This trade represents a 8.27% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Orchestra BioMed Stock Up 0.5%

OBIO stock opened at $4.00 on Wednesday. The company has a 50 day moving average of $4.27 and a two-hundred day moving average of $4.27. The company has a market cap of $239.52 million, a price-to-earnings ratio of -4.12 and a beta of 0.52. Orchestra BioMed Holdings, Inc. has a 12-month low of $2.20 and a 12-month high of $5.42. The company has a quick ratio of 7.01, a current ratio of 7.03 and a debt-to-equity ratio of 0.35.

Orchestra BioMed (NASDAQ:OBIO) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.07. Orchestra BioMed had a negative net margin of 166.96% and a negative return on equity of 157.46%. The business had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $0.92 million. On average, equities analysts anticipate that Orchestra BioMed Holdings, Inc. will post -1.54 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on OBIO. B. Riley Financial reduced their price target on Orchestra BioMed from $12.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday. Wall Street Zen lowered shares of Orchestra BioMed from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings downgraded shares of Orchestra BioMed from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, April 21st. Chardan Capital reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Orchestra BioMed in a research note on Thursday, March 12th. Finally, Barclays upped their price objective on shares of Orchestra BioMed from $12.00 to $13.00 and gave the stock an “overweight” rating in a report on Wednesday, May 13th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Orchestra BioMed currently has an average rating of “Moderate Buy” and a consensus target price of $13.60.

Orchestra BioMed News Summary

Here are the key news stories impacting Orchestra BioMed this week:

• Positive Sentiment: Multiple insiders bought shares, including Director Eric Fain’s purchase of 20,000 shares and additional buying by David P. Hochman and Jason Aryeh. Insider buying is often read as a vote of confidence in the company’s outlook. SEC filing for Eric Fain purchase
• Positive Sentiment: HC Wainwright reiterated a Buy rating and $10 price target, while slightly raising near-term and FY2026 earnings estimates. That suggests analysts still see meaningful upside from current levels. Benzinga report
• Positive Sentiment: The company said management will participate in the Jefferies Global Healthcare Conference, which can raise visibility with investors and potential partners. Conference announcement
• Neutral Sentiment: B. Riley Financial lowered its price target to $10 from $12 but kept a Buy rating. The cut is a mild headwind, but the unchanged bullish rating limits the downside impact. Benzinga report

Hedge Funds Weigh In On Orchestra BioMed

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. bought a new position in shares of Orchestra BioMed in the fourth quarter valued at approximately $38,000. Virtu Financial LLC bought a new stake in shares of Orchestra BioMed during the 4th quarter worth $57,000. Creative Planning acquired a new position in Orchestra BioMed in the 2nd quarter valued at $40,000. XTX Topco Ltd bought a new position in Orchestra BioMed in the 2nd quarter worth $45,000. Finally, Balyasny Asset Management L.P. bought a new position in Orchestra BioMed in the 4th quarter worth $76,000. Institutional investors and hedge funds own 53.20% of the company’s stock.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.